POSITION STATEMENT

Nutrition

Early diet and the risk of coeliac disease. An update 2024 position paper by the ESPGHAN special interest group on coeliac disease

Hania Szajewska1 | Raanan Shamir2 | Renata Auricchio3 | Anna Chmielewska4 | Jernej Dolinsek5 | Laura Kivelä6,7,8,9 | Sibylle Koletzko10,11 | Ilma R. Korponay-Szabo12,13 | Elin M Hård Af Segerstad14,15,16 | M. Luisa Mearin17 | Caroline Meijer-Boekel17 | Carmen Ribes Konickx18 | Alfonso Rodriguez-Herrera19 | Ketil Stordal19,20 | Riccardo Troncone3 | Margreet Wessels21

1Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland
2Institute of Gastroenterology, Nutrition and Liver Disease, Schneider Children's Medical Center of Israel, School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
3Department of Translational Medical Sciences and European Laboratory for the Investigation of Food Induced Diseases, University Federico II, Naples, Italy
4Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden
5Department of Pediatrics, University Medical Center Maribor, Maribor, Slovenia
6Celiac Disease Research Center, Tampere University, Tampere, Finland
7Department of Pediatrics, Tampere University Hospital, Tampere, Finland
8Children's Hospital, Helsinki University Hospital, Helsinki, Finland
9Department of Paediatric Research, Faculty of Medicine, University of Oslo, Oslo, Norway
10Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Munich, Germany
11Department of Pediatrics, School of Medicine Collegium Medicum, Gastroenterology and Nutrition, University of Warmia and Mazury, Olsztyn, Poland
12Celiac Disease Center, Heim Pál National Paediatric Institute, Budapest, Hungary
13Department of Paediatrics, University of Debrecen, Debrecen, Hungary
14Department of Pediatric Research, Oslo University Hospital, Oslo, Norway
15Unit of Celiac and Diabetes Research, Clinical Sciences Malmö, Lund university, Lund, Sweden
16Department of Pediatrics, Skane University Hospital, Malmö, Sweden
17Department of Paediatric Gastroenterology, Leiden University Medical Center - Willem Alexander Children's Hospital, Leiden, The Netherlands
18Pediatric Gastroenterology, La Fe University Hospital, Instituto de Investigacion Sanitaria La FE Valencia, Valencia, Spain
19St Luke's General Hospital, University College Dublin, Dublin, Ireland
20Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
21Department of Paediatrics, Rijnstate Hospital, Arnhem, The Netherlands

Correspondence
Hania Szajewska, The Medical University of Warsaw, Department of Paediatrics 2wirki I Wigury 63A, 02-091 Warsaw, Poland.
Email: hszajewska@wum.edu.pl

Abstract
This position paper by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Special Interest Group on Coeliac Disease (SIG-CD) presents an update to the 2016 recommendations concerning early diet
and the risk of coeliac disease (CD). This update adheres to the policy that mandates reviewing guidelines every 5 years, particularly when new data emerge. The 2024 statements and recommendations are essentially similar to the 2016 recommendations. Breastfeeding, whether any amount, exclusive, or of any duration, does not reduce the risk of developing CD. Introducing gluten into an infant’s diet at any time between completed 4 months (≥17 weeks) and 12 months of age does not affect the cumulative incidence of CD, although earlier introduction may lead to earlier seroconversion and CD. In observational studies involving cohorts with a known risk for CD, consuming a high amount of gluten compared to a low amount during weaning and in the subsequent childhood years—specifically the first 2–3 years, and even up to 5 years in some studies—was associated with an increased risk for CD. However, the specific optimal amounts of gluten consumption remain undetermined due to insufficient evidence on safe thresholds, and the impact of restricting gluten in the diet of healthy children of unknown risk for CD is unknown. Thus, any recommendation on the gluten amount is currently unjustifiable for the general population and infants with known HLA risk types. There is no specific guidance on the type of gluten-containing foods to be introduced at weaning.

EARLY DIET AND THE RISK OF COELIAC DISEASE. ESPGHAN SIG-CD 2024

RECOMMENDATIONS FOR INFANTS WITH KNOWN OR UNKNOWN GENETIC RISK FOR COELIAC DISEASE

- Breastfeeding: Follow the recommendations for the general population.
- Breastfeeding during gluten introduction: No specific guidance.
- Timing of gluten introduction: Introduce gluten-containing foods as part of complementary feeding at any age after completing 4 months (≥17 weeks) of age.
- Gluten amount at weaning & beyond: No specific guidance.
- Type of gluten after weaning: No specific guidance.
- Maternal gluten intake during pregnancy & lactation: No specific guidance.
- Genetic predisposition: No specific guidance.

KEYWORDS
celiac disease risk, gluten amount, gluten introduction, infant feeding, infant nutrition

1 | BACKGROUND

In 2016, the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) issued recommendations on early feeding and gluten introduction and the risk of developing coeliac disease (CD) during childhood. These recommendations were confirmed in 2017 by the ESPGHAN Committee on Nutrition. The recommendations emphasised that while breastfeeding offers numerous health benefits, it does not reduce the risk of CD, whether it overlaps with the introduction of gluten or not. It is also stated that introducing gluten to an infant’s diet between 4 and 12 months of age does not affect the risk of developing celiac disease autoimmunity (CDA)—defined as the presence of anti-transglutaminase or anti-endomysial antibodies—or CD, up to the age of 3 years. However, in children with a known genetic risk of CD, introducing gluten earlier may lead to the earlier onset of CDA and CD without affecting the cumulative incidence of CD. Observational studies suggested that consuming high amounts of gluten (in the upper quartile compared to the lower quartile) during the initial weeks after its introduction and throughout infancy might increase the risk of CD. However, the amount of gluten considered optimal for consumption during weaning was not determined. Even though only individuals carrying one or more of the CD risk alleles can develop CD while on a gluten-containing diet, recommendations were intended for all infants since the genetic risk is typically unknown in infants when introducing solid foods.

With the emergence of new evidence since the 2016/2017 recommendations, a systematic review was...
carried out in 2023 to assess how early infant feeding practices affect the risk of developing CDA and CD. The primary objective of this review was to update the ESPGHAN position paper from 2016 based on this systematic review and the most recent publications regarding early feeding practices/diet and their impact on CDA and CD risk. This update adheres to the policy that mandates reviewing guidelines every 5 years, particularly when new data emerge. This document represents ESPGHAN's current position, which updates or reaffirms previous recommendations in the context of recent findings.

2 | METHODS

Group composition and conflict of interest disclosure

The group included members from the ESPGHAN Special Interest Group on Coeliac Disease (SIG-CD) and representatives from the ESPGHAN Committees on Nutrition and Allied Health Professionals. The members of the group were physicians and allied health professionals, as well as experts in paediatrics, paediatric gastroenterology, paediatric nutrition, and dietetics. All potential conflicts of interest have been disclosed and are registered on the ESPGHAN website. None were considered related to this paper.

2.1 | Research questions

The systematic review published earlier guided the development of this document. With one exception, the same research questions as in the review were considered (Table 1).

2.2 | Literature search

The initial review was conducted in May 2022, using the databases PubMed, EMBASE, and the Cochrane Library. Additional searches were performed from May 2022 to June 2023 to include new findings. The group reached a consensus that a targeted search in PubMed would be sufficient. A list of newly identified publications is available upon request. In the sections below, only those considered relevant were cited.

2.3 | Evidence and recommendations

The modified Delphi process was used to establish consensus on the recommendations. In the first round, each group member was asked to vote next to each recommendation, choosing from the following options: strongly agree, agree, neither agree nor disagree, disagree, or strongly disagree. Members were also given the opportunity to comment or suggest alternative wording for each recommendation. Voting was kept anonymous. At least 80% agreement from the team was needed on each recommendation. If a recommendation did not get enough agreement, it was revised based on the team's feedback and was sent back for a second round of voting. In this second round, team members knew the overall group scores and comments from the first round, which helped them reconsider their positions. Voting was again anonymous. Once everyone agreed, the recommendation made it into the final document.

2.4 | ESPGHAN consultation

The ESPGHAN SIG-CD, the Committee on Nutrition, and the Gastroenterology Committee reviewed the draft to ensure the inclusion of their expert insights. Additionally, the draft was posted on the ESPGHAN website, inviting ESPGHAN members to provide written feedback.

What is Known

- Previous European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) position papers have addressed the relationship between breastfeeding, gluten introduction in infants, and the risk of developing coeliac disease (CD) during childhood.
- There is a recognised need for an update considering new evidence.

What is New

- The ESPGHAN Special Interest Group on Coeliac Disease has formulated key questions concerning early feeding practices/diet and the risk of coeliac disease autoimmunity (CDA) and CD.
- Recommendations from previous position papers have been updated or reaffirmed based on the latest published evidence.
- Knowledge gaps were identified, underscoring the need for further research to better understand the impact of early feeding practices on the risk of CDA/CD.
### Table 1: 2024 statements and recommendations on early diet and the risk of coeliac disease.

<table>
<thead>
<tr>
<th>Question</th>
<th>Statements</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Q1. BF and CD.</strong></td>
<td>Any BF compared with no BF has not been shown to reduce the risk of developing CD during childhood or to delay the development of CD.</td>
<td>Recommendations on BF for infants with known or unknown genetic risk should not be modified due to considerations regarding prevention of CD.</td>
</tr>
<tr>
<td><strong>Q2. BF at the time of gluten introduction and CD.</strong></td>
<td>Breastfeeding at the time of gluten introduction, as compared to gluten introduction after weaning from BF, has not been shown to reduce the risk of developing CD during childhood.</td>
<td>Introducing gluten while the infant is being breastfed cannot be recommended as a means of reducing the risk of developing CD.</td>
</tr>
<tr>
<td><strong>Q3. Timing of gluten introduction.</strong></td>
<td>The age of gluten introduction between completed 4 months (≥17 weeks) and 12 months of age does not seem to influence the absolute risk of developing CDA or CD during childhood.</td>
<td>Gluten can be introduced into the infant’s diet at any time between completed 4 months (≥17 weeks) and 12 months of age without affecting the cumulative risk of CDA or CD development during childhood.</td>
</tr>
<tr>
<td><strong>Q4. Amount of gluten at weaning (and later) and CD.</strong></td>
<td>Observational and case-control studies suggest that the consumption of a higher amount of gluten at weaning and/or thereafter may increase the risk of CDA and CD in genetically at-risk children.</td>
<td>No recommendation can be made regarding the amount of gluten intake at weaning and up to 2-3 years of age for infants of unknown risk for CD. Similarly, for infants with a known CD risk, no recommendation can be made. We recommend awaiting the results of ongoing intervention studies before any guidance can be given on the consumption of gluten amounts during the first 2 or 3 years of life.</td>
</tr>
<tr>
<td><strong>Q5. Type of gluten at introduction and after weaning.</strong></td>
<td>The type of gluten at introduction was not shown to modify the risk for developing CD.</td>
<td>No recommendation can be made regarding the source and type of gluten-containing food to be used at food introduction or after weaning.</td>
</tr>
<tr>
<td><strong>Q6. Gluten intake by the mother during pregnancy &amp; lactation.</strong></td>
<td>There is inconclusive evidence on the link between maternal gluten intake during pregnancy and the risk of CD in the offspring, and no evidence regarding the impact of maternal gluten intake during lactation.</td>
<td>There is no evidence to give specific recommendations on gluten intake by the mother during pregnancy and lactation.</td>
</tr>
<tr>
<td><strong>Q7. Genetic predisposition.</strong></td>
<td>Observational studies, including cohort and case-control studies, do not provide evidence that the effect of high gluten intake on CD and CDA development is related to different HLA risk types.</td>
<td>There is not enough evidence to give differentiated recommendations on gluten consumption for various HLA risk types.</td>
</tr>
</tbody>
</table>

Abbreviations: BF, breastfeeding; CD, coeliac disease; CDA, coeliac disease autoimmunity.
3 | STATEMENTS & RECOMMENDATIONS

Table 1 summarises the clinical questions, the 2024 statements and recommendations. For a concise summary of the recommendations and practical tips for introducing gluten-containing foods, please refer to Tables S1 and S2. Below, detailed explanations are provided to clarify any modifications or reaffirmations of the recommendations initially made in 2016.

Q1. Breastfeeding (BF) and CD. Is the risk of developing CD reduced by exclusive or any BF? Is the age when CD develops influenced by exclusive or any BF? Is the risk of developing CD affected by BF duration?

The 2023 systematic review, which analyzed findings from randomised controlled trials (RCTs), cohort studies, and case-control studies, found that for individuals at genetic risk of developing CD (those with HLA DQ2/DQ8 alleles), neither exclusive nor any BF, nor the duration of BF, was associated with a reduced risk of developing CDA or CD during childhood.

Since a 2023 systematic review, seven newly identified articles were considered relevant, and full papers were retrieved. Among these, the only study contributing new data was a retrospective case-control study from Iran. This study compared 186 children diagnosed with CD (mean age: 4.8 years) from a single centre with 186 non-CD controls (mean age: 4.1 years). The two groups exhibited significant differences in several critical aspects, including the prevalence of birth weight below 2500 g (35.5% in the CD cohort vs. 7% in controls, p < 0.001), maternal education (p < 0.008, urban vs. rural residency, p < 0.001), and caesarean section rates (28% vs. 15.6%, respectively, p < 0.004). These factors are known to influence the rates of both any and exclusive BF. Infant diet in the first 6 months of life was reported for both the CD cohort (cases) and controls: 65.1% of cases were exclusively breastfed compared to 83.3% of controls, BF in combination with formula feeding occurred in 28% of cases versus 12.9% of controls, and 7% of cases were not breastfed in contrast to 3.8% of controls (p < 0.001). Due to the inadequate matching of cases and controls, the retrospective character of the study, a high percentage of mothers being illiterate, and potential recall bias, we did not consider this study relevant to the data or conclusions drawn from the 2023 systematic review.

The 2023 systematic review by Alotiby et al. on the role of BF in the development of immune-mediated diseases, with CD being one of them, examined a different time frame, and several recent important publications from large birth cohort studies were not included. In addition, no methodology to explore the evidence based on the quality of the included studies was applied in contrast to the 2023 review by Szajewska et al. Therefore, we decided to base our statements and recommendations on the more robust review findings by Szajewska et al. Compared to the 2016 position paper, the statements and recommendations have remained the same (refer to Table 1).

Q2. BF at the time of gluten introduction and CD. Is the risk of CD reduced if gluten is consumed while the infant is still being breastfed?

The 2023 systematic review concluded that, based on a meta-analysis of four case-control studies, there is a suggested decreased risk of CD when gluten is introduced during BF. However, this association was not supported by RCTs and cohort studies. No new studies were identified. Compared to the 2016 position paper, there have been no major changes in the statements and recommendations (refer to Table 1).

Q3. Timing of gluten introduction: Is the risk of developing CD influenced by the timing of gluten introduction? Does the age at gluten introduction affect the age when CD develops?

No new studies have emerged since the 2023 systematic review. The timing of gluten introduction between completed 4 to 12 months of life has not been linked to a higher overall risk of developing CDA or CD. One RCT indicated that introducing small amounts of gluten at 6 months of age could lead to an earlier onset of CD compared to later age (12 months). This finding aligns with the biological expectation due to earlier exposure. However, early gluten introduction did not result in a reduced cumulative incidence of CD after the age of 3 years. Results from some observational cohort studies suggest that gluten introduction before 6 months was associated with a lower risk of later CD, whereas other cohort studies observed similar risks. In summary, no substantial revisions have been necessary for the statements and recommendations previously outlined in the 2016 position paper (refer to Table 1).

Q4. Amount of gluten at weaning (and later) and CD. Is the amount of gluten consumed an independent risk factor for CD development in early childhood? Is there a threshold level for the amount of gluten consumption for this risk?

No new studies have emerged since the 2023 systematic review. This review concluded that both cohort and case-control studies suggest that consuming a higher amount of gluten at weaning and thereafter may increase the risk for CDA and CD in genetically predisposed children (Table S3). Cohort studies also indicated that a higher daily gluten intake during the first 5 years of life is associated with an increased risk for CDA and CD. The variations in specific daily amounts reported in these studies are possibly due to differences in dietary habits, but also very likely due to different dietary assessment methods as well as statistical analyses used (see Tables S3 and S4, which...
shows the gluten content in different foods). Importantly, all the studies identified a dose-dependent risk association, indicating that higher gluten intake is correlated with an increased risk of CD. However, whether there is a safe threshold or optimal amount for gluten consumption has not yet been established, and there is currently no evidence to suggest that gluten restriction can prevent the development of CD. Furthermore, most children will not develop CD regardless of their gluten intake, and the nutritional and psychosocial consequences of gluten restriction in healthy children are not well understood. Therefore, it is not possible to make a general recommendation about gluten intake at the population level. Additionally, it is not yet feasible to determine a specific gluten threshold for children with a known risk for CD or to define a group of children who may benefit from gluten restriction.

A 2023 mini-review by Aronsson et al.9 provided an overview of ongoing or completed RCTs that focused on dietary interventions during early childhood to prevent CD. This review introduced two ongoing RCTs involving infants. First, the PreCiSe study (ClinicalTrials.gov Identifier NCT03562221), evaluating the effect of gluten introduction after 3 years of age compared to no dietary restrictions with/without probiotics in children with known risk for CD. Second, the GRAIn study (ClinicalTrials.gov Identifier: NCT04593888), investigating the effect of a gluten-reduced diet versus no gluten restriction up to age 3 years. In the future, the results of these studies will hopefully provide evidence supporting more detailed recommendations about the optimal gluten amount in early childhood and risk for later CD.

Key differences between previous (2016) and current (2024) recommendations include:

- The 2016 recommendation focused on the period just after introducing gluten, whereas the 2024 version extends the follow-up period to up to 5 years of life.
- The 2024 recommendation emphasises genetic predisposition and details the types of studies (observational, case-control, and cohort) that contribute to the development of the guidelines.
- The 2024 recommendation emphasises the lack of evidence for an optimal amount or safe threshold of gluten intake, the potential nutritional, economic and psychosocial consequences of a gluten-free or gluten-restricted diet in healthy children at both known and unknown risk (population level), and the challenges in limiting guidance to only those at known risk of developing CD.
- The 2024 recommendation suggests that for children with a known risk for CD, avoiding large amounts of gluten during the first 5 years of life may be beneficial. However, a detailed recommendation on the optimal amount of gluten cannot currently be given.

Q5. Type of gluten: Is CD risk influenced by the type of cereal (wheat, rye, barley) consumed at gluten introduction or later during childhood? Does the type of gluten-containing products (bread, porridge, follow-on formula) at gluten introduction influence CD risk?

The 2023 systematic review3 found that no RCTs reported on the risk of CDA or CD in relation to the intake of different types of gluten-containing products. The review included one observational study from Sweden, focusing on a population with a known CD risk (TEDDY cohort), which reported an increased risk of CD associated with a daily bread intake of more than about half a slice of bread compared to no bread intake, but with an equal amount of gluten from other foods at 12 months.15 Additionally, a meta-analysis of two Swedish case-control studies16,17 suggested an increased risk of CD when gluten was introduced with gluten-containing, cereal-based follow-up formula, as opposed to introducing gluten with solid foods.

In the Swedish sub-cohort of the TEDDY observational birth cohort study18 involving children from the general population who are genetically predisposed to type 1 diabetes and CD, 3-day food records up to age 2 years were analysed. This analysis revealed that specific gluten-containing foods consumed at different ages were associated with an increased risk of CDA when adjusting for the total daily gluten intake. Notably, at 9 months, consuming up to one portion of porridge daily was linked to a higher risk of CDA (HR 1.53; 95% CI: 1.05, 2.23; p = .026) compared to no porridge intake. Similarly, at 12 months, a daily intake of more than half a slice of bread compared with no bread intake was associated with increased risks of CDA (HR: 1.47; 95% CI: 1.05, 2.05; p = .023) and CD (HR: 1.79; 95% CI: 1.10, 2.91; p = .0019). At 18 months, each bottle of daily intake of cereal-based follow-up formula consumed was linked to a heightened risk of CD (HR: 1.16; 95% CI: 1.00, 1.33; p = .047). However, the study found no association between the type of gluten-containing grain (wheat or rye) consumed up to 24 months and the risk of CDA or CD, when also considering the total gluten intake. This study did not investigate the type of gluten at the time of its introduction into the diet. Overall, compared to the 2016 position paper, no changes have been made in the statements and recommendations on the type of gluten (refer to Table 1).

Q6. Gluten intake by the mother during lactation. Is CD risk in the offspring influenced by consumption of a gluten-free diet versus a gluten-containing diet during pregnancy and lactation?
The 2023 systematic review found no reported data on whether the risk of CD in offspring is affected by the mother's consumption of either a gluten-free or a gluten-containing diet during lactation. There have been no subsequent publications that address this specific topic. The impact of maternal gluten intake during pregnancy on the offspring's CD risk remains uncertain. The TEDDY study found no association, while the MoBa study indicated that low gluten and high fibre intake during pregnancy might reduce the risk of CD in children.

Q7. Genetic predisposition. Does the amount of gluten consumed by the infant have different effects on risk for CDA and CD development in relation to different HLA risk alleles?

As described in the 2023 systematic review, four observational studies, including two cohort studies and one case-control study, presented inconclusive results on the link between feeding practices and the risk of CD in children with various HLA genotypes. Since then, no new studies have been identified.

The PreventCD cohort found no significant association between the amounts of gluten consumption and the development of CD by age 5, except in children with the DQ2.2/DQ7 haplotype (HR 5.81, 95% CI, 1.18–28.74). For this group, the increased risk was related only to the initial increase in gluten consumption between 11 and 18 months of age, not to the overall daily gluten intake or any other parameters. The DAISY study observed no association between gluten intake at 1 year and the development of CDA/CD, considering the child's HLA genotype (HR not reported, p > 0.15). Similarly, a nested case-control study within the Norwegian Mother and Child cohort indicated that the association between gluten intake at 18 months and the development of CD was not dependent on the child's HLA genotype. The nested case-control study of the Swedish TEDDY cohort investigated the effect of high gluten intake (defined as in the upper tertile, e.g., > 5 g/d) before seroconversion in relation to three different HLA risk types: high-risk group (DR3-DQ2 homozygotes), moderate risk group (DR3-DQ2 heterozygotes), and low-risk group (only DR4-DQ8 without DR3-DQ2). More cases than controls were found in the upper tertile of gluten intake, but the hazard ratio was not significantly different between the three HLA risk groups. This indicated that the risk-increasing effect of high gluten intake is unrelated to the HLA risk alleles. These association studies do not provide evidence to give specific recommendations concerning gluten intake during infancy and the first years of life based on HLA risk type (refer to Table 1). It can be hypothesised that for infants at high HLA risk, the inherent genetic risk is so pronounced that the amount of gluten consumed (within the ranges typically seen at the population level) may not contribute measurably to the actual risk.

4 | RESEARCH GAPS

We have identified several key areas where further research is needed. These gaps highlight the potential for advancing our understanding of early diet and the risk of CD. Addressing these areas will be crucial in developing more precise guidelines and interventions. The primary research gaps identified include:

- Conducting RCTs to determine if a safe threshold for daily gluten consumption exists at different ages for children with known risk for CD.
- Evaluating gluten-restricted diets in young children should include assessing these diets’ nutritional effects on fibre and whole grain intake and wider nutritional and psychological impacts. This assessment should also consider the economic aspects of choosing gluten-free or gluten-low alternatives, as well as the societial implications.
- Further evaluating the relationship between HLA genotypes, the amount of gluten at introduction and early childhood, and the subsequent risk of CD.
- Until now, research has primarily focused on introducing gluten up to 12 months of age; therefore, it is crucial to evaluate the effects of further delaying its introduction. Such a delay might be justified by the age-related development of immunity and reduced susceptibility to gastrointestinal infections.
- Conducting RCTs to investigate the impact of proactively introducing gluten in natural quantities from age 4 months, which may be considered a controversial practice, as opposed to after 6 months, on the cumulative risk of CD.
- Assessing the impact of different dietary sources and types of foods containing gluten, including those with different textures and in combination with other foods, at food introduction and in early childhood.
- Further exploring the effects of maternal gluten consumption during pregnancy and lactation in various populations.
- Exploring the effects of prenatal and early life dietary exposures in addition to gluten intake, including micronutrients, other dietary components, foods, and dietary patterns.

ESPGHAN DISCLAIMER

ESPGHAN is not responsible for the practices of physicians and provides guidelines and position papers as indicators of best practice only. Diagnosis and treatment is at the discretion of the healthcare provider.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.
REFERENCES


SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.